323 related articles for article (PubMed ID: 24053191)
41. Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open-label extension study.
Ito T; Fujimori N; Honma Y; Kudo A; Hijioka S; Katsushima S; Kimura Y; Fukutomi A; Hisamatsu S; Nakajima A; Shimatsu A
Asia Pac J Clin Oncol; 2021 Oct; 17(5):e153-e161. PubMed ID: 32757459
[TBL] [Abstract][Full Text] [Related]
42. The safety of lanreotide for neuroendocrine tumor.
Godara A; Siddiqui NS; Byrne MM; Saif MW
Expert Opin Drug Saf; 2019 Jan; 18(1):1-10. PubMed ID: 30582380
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
Lucas T; Astorga R;
Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
[TBL] [Abstract][Full Text] [Related]
44. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
Ducreux M; Ruszniewski P; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Hammel P; Rougier P
Am J Gastroenterol; 2000 Nov; 95(11):3276-81. PubMed ID: 11095353
[TBL] [Abstract][Full Text] [Related]
45. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
46. Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs.
Lenotti E; Alberti A; Spada F; Amoroso V; Maisonneuve P; Grisanti S; Baggi A; Bianchi S; Fazio N; Berruti A
Front Endocrinol (Lausanne); 2021; 12():669484. PubMed ID: 33986731
[TBL] [Abstract][Full Text] [Related]
47. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
Oberg K
Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
[TBL] [Abstract][Full Text] [Related]
48. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
Bajetta E; Procopio G; Catena L; Martinetti A; De Dosso S; Ricci S; Lecchi AS; Boscani PF; Iacobelli S; Carteni G; De Braud F; Loli P; Tartaglia A; Bajetta R; Ferrari L
Cancer; 2006 Nov; 107(10):2474-81. PubMed ID: 17054107
[TBL] [Abstract][Full Text] [Related]
49. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.
Mazziotti G; Giustina A
Pituitary; 2010; 13(1):60-7. PubMed ID: 19189218
[TBL] [Abstract][Full Text] [Related]
50. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
[TBL] [Abstract][Full Text] [Related]
51. Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors.
Dromain C; Loaiza-Bonilla A; Mirakhur B; Beveridge TJR; Fojo AT
Oncologist; 2021 Apr; 26(4):e632-e638. PubMed ID: 33393112
[TBL] [Abstract][Full Text] [Related]
52. Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity With Lanreotide Autogel/Depot (LAN) Versus Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):6-7. PubMed ID: 27168103
[No Abstract] [Full Text] [Related]
53. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
Dromain C; Pavel ME; Ruszniewski P; Langley A; Massien C; Baudin E; Caplin ME;
BMC Cancer; 2019 Jan; 19(1):66. PubMed ID: 30642293
[TBL] [Abstract][Full Text] [Related]
54. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
[TBL] [Abstract][Full Text] [Related]
55. Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies.
Adelman DT; Van Genechten D; Megret CM; Truong Thanh XT; Hand P; Martin WA
Adv Ther; 2019 Dec; 36(12):3409-3423. PubMed ID: 31612358
[TBL] [Abstract][Full Text] [Related]
56. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
57. Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms.
Laskaratos FM; Armeni E; Shah H; Megapanou M; Papantoniou D; Hayes AR; Navalkissoor S; Gnanasegaran G; von Stempel C; Phillips E; Furnace M; Kamieniarz L; Kousteni M; Luong TV; Watkins J; Mandair D; Caplin M; Toumpanakis C
Endocrine; 2020 Jan; 67(1):233-242. PubMed ID: 31556004
[TBL] [Abstract][Full Text] [Related]
58. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Pokuri VK; Fong MK; Iyer R
Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
[TBL] [Abstract][Full Text] [Related]
59. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
Enzler T; Fojo T
Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
[TBL] [Abstract][Full Text] [Related]
60. Somatostatin analogs in pregnant patients with neuroendocrine tumor.
Meoni G; Giommoni E; Petreni P; Pillozzi S; Mazzoni F; Pellegrini E; Brugia M; Lunghi A; Muto A; Antonuzzo L
Anticancer Drugs; 2020 Nov; 31(10):1096-1098. PubMed ID: 32590392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]